Keyword: Jardiance

Lilly provided a forecast for next year that beat analysts’ expectations—welcome news as blockbuster Cialis faces generic rivals.

Johnson & Johnson's Janssen is using Twitter to get the word out about the link between Type 2 diabetes and cardiovascular risks.

With outcomes data showing Farxiga lowers hospitalizations for heart failure or CV deaths against placebo, AZ plans to file for a new FDA label.

Generic competition is weighing on Cialis, but luckily for Lilly, several new drugs are on the upswing, including top performers Trulicity and Taltz.

It’s been more than a year since J&J showed Invokana could improve heart safety, but the company's reps can finally tout those benefits.

With data showing Farxiga can reduce hospitalizations for heart failure or CV deaths against placebo, AZ plans to seek a label update.

The FDA has raised red flags about a potentially serious flesh-eating disease in patients taking SGLT2 inhibitors.

Lilly CEO David Ricks says casting off Elanco will allow it to allocate more capital to its human health efforts.

J&J’s Invokana will have to wait longer for the FDA to decide on a key label expansion, but it's still got good news to celebrate.

In a new post-hoc analysis of Jardiance's CV outcomes test, investigators found that the drug reduced kidney disease progression.